1 / 10

PharmaMiner : Geometric Mining of Pharmacophores

PharmaMiner : Geometric Mining of Pharmacophores. PharmaMiner. We define a Joint Pharmacophore Space by extracting 3D descriptors from diverse libraries/targets Analysis of pharmacophores in the Joint Space Classification and clustering for understanding biological activity

vesta
Télécharger la présentation

PharmaMiner : Geometric Mining of Pharmacophores

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PharmaMiner: Geometric Mining of Pharmacophores

  2. PharmaMiner • We define a Joint Pharmacophore Space by extracting 3D descriptors from diverse libraries/targets • Analysis of pharmacophores in the Joint Space • Classification and clustering for understanding biological activity • Screening for compounds based on presence and/or absence of activity • Fragment-based discovery and scaffold hopping • Flexible definition of pharmacophoric features (donor, acceptor, hydrophobic core, etc.)

  3. Applications of PharmaMiner • Determine what makes compounds active against a target. • Develop pharmacophore models based on analysis results. • Find what features impart specific biological activity (e.g., BBB permeability). • Screen compounds for activity against single/multiple targets • Selectivity queries for combination of properties • Diversity analysis in 3D space • Scaffold hopping

  4. Key Benefits • Only automatic tool that analyzes the 3D space of pharmacophores • Identification of activity against a target based on a set of actives and inactives (clustering) • Unique exploration of the pharmacophore space through biological activity (classification) • Unique querying using proximity and/or distance from clusters • Specification of selectivity, toxicity, absorption, side-effects

  5. Validation Studies Activity prediction of 11 NCI cancer datasets (cell-based assays) based on the analysis of the Joint Pharmacophore Space

  6. Chosen Pharmacophoric Features • Cations • Anions • Hydrogen Bond Donors • Hydrogen Bond Acceptors • Hydrophobic Centers • Aromatic Rings

  7. Cluster Analysis • Many clusters of pharmacophores in the Joint Space are enriched with respect to specific activities • Examples of some positive clusters (i.e., clusters with a much higher percentage of actives than a random set)

  8. Not All Clusters Are Enriched! • Clusters involving anions show strong negative significance:  • Each cluster can be annotated with the presence or absence of an activity or property. This enables screening of compounds for selectivity against multiple targets or properties.

  9. Prediction Pipeline Extract all pharmacophoricfeatures Clustering Significant cluster centers Molecular DB Pharmacophores Classification Model Feature Vector Vector representation of molecules Result Classifier

  10. PharmaMineris Complementary to SigFinder • Graph based approach allows more flexibility and computational efficiency; However, 3D analysis has better accuracy • Pharmacophoric features allow greater abstraction • Scaffold hopping • Possible to combine the two techniques

More Related